| Intercept |
10.4 (10.2, 10.7) |
<0.001 |
| Hospital type (Ref=general) |
|
|
| Specialized |
0.2 (0.1, 0.3) |
<0.001 |
| Age at diagnosis (year) (Ref≥65) |
|
|
| <45 |
0.2 (0.0, 0.3) |
0.030 |
| 45−54 |
0.1 (0.0, 0.3) |
0.080 |
| 55−64 |
0.0 (−0.2, 0.1) |
0.443 |
| Sex (Ref=females) |
|
|
| Males |
0.0 (−0.1, 0.1) |
0.828 |
| Education (Ref=primary school or below) |
|
|
| Junior high school |
0.0 (−0.1, 0.1) |
0.573 |
| Senior high school |
0.1 (−0.1, 0.2) |
0.388 |
| Undergraduate or higher |
0.2 (0.0, 0.4) |
0.015 |
| Occupation (Ref=self-employee or unemployee) |
|
|
| Farmer |
0.0 (−0.2, 0.1) |
0.604 |
| Enterprise or company employee/worker |
0.1 (−0.1, 0.2) |
0.248 |
| Retiree |
0.0 (−0.2, 0.2) |
0.983 |
| Staff in institution/civil servant |
0.5 (0.3, 0.7) |
<0.001 |
| Other |
0.0 (−0.3, 0.4) |
0.879 |
| Healthcare insurance type (Ref=new rural cooperative medical scheme) |
|
|
| Urban employee basic medical insurance |
0.2 (0.0, 0.3) |
0.034 |
| Urban resident basic medical insurance |
0.1 (0.0, 0.2) |
0.196 |
| Commercial insurance |
−0.6 (−1.1, −0.1) |
0.031 |
| Self-financed |
0.1 (−0.3, 0.4) |
0.663 |
| Other |
0.3 (−0.1, 0.7) |
0.132 |
| Previous-year household income (CNY) (Ref<20,000) |
|
|
| 20,000−39,999 |
0.1 (−0.1, 0.3) |
0.240 |
| 40,000−69,999 |
0.2 (0.0, 0.3) |
0.032 |
| ≥70,000 |
0.2 (0.0, 0.4) |
0.022 |
| Clinical stage (Ref=I) |
|
|
| II |
−0.1 (−0.2, 0.0) |
0.100 |
| III |
0.1 (−0.1, 0.2) |
0.375 |
| IV |
0.1 (−0.1, 0.3) |
0.183 |
| Pathologic type (Ref=others) |
|
|
| Adenocarcinoma |
0.0 (−0.1, 0.1) |
0.810 |
| Therapeutic regimen (Ref=surgery) |
|
|
| Chemotherapy |
−0.1 (−0.4, 0.2) |
0.493 |
| Surgery and postoperative chemotherapy |
−0.2 (−0.4, −0.1) |
<0.001 |
| Symptomatic treatment |
−0.1 (−0.2, 0.1) |
0.552 |
| Concurrent chemoradiotherapy |
−0.1 (−0.4, 0.1) |
0.289 |
| Radiotherapy |
0.0 (−0.5, 0.5) |
0.934 |
| Neoadjuvant chemotherapy and surgery |
−0.2 (−0.3, −0.1) |
<0.001 |
